论文部分内容阅读
目的分析肿瘤标记物检测和核素骨显像对肺癌早期骨转移的诊断价值。方法对65例肺癌患者进行SPECT全身核素骨显像的同时,用化学发光免疫分析法测定血清癌胚抗原(CEA)、可溶性细胞角蛋白19片段(CYFRA21-1)、神经元特异性烯醇酶(NSE)。另选择肺良性疾病患者70例用化学发光免疫分析法检测血清CEA、CYFR21-1、NSE结果作为对照。结果有骨转移的肺癌患者的血清CEA、CYFR21-1、NSE浓度及阳性率明显高于无骨转移及肺良性疾病患者;骨显像阳性组和骨显像阴性组分别与肺良性疾病组之间CEA、CYFR21-1、NSE检测结果存在显著性差异(P<0.01)。结论常规做全身骨显像,对于临床的判断、分期和确定治疗方法具有重要意义。
Objective To analyze the diagnostic value of tumor marker detection and radionuclide bone imaging in early stage of lung cancer with bone metastasis. Methods SPECT whole body radionuclide bone imaging was performed in 65 patients with lung cancer. Chemiluminescence immunoassay was used to detect the serum CEA, CYFRA21-1, Enzyme (NSE). Another 70 cases of patients with benign lung diseases using chemiluminescence immunoassay for the detection of serum CEA, CYFR21-1, NSE results as a control. Results The serum concentrations of CEA, CYFR21-1 and NSE and the positive rates of serum CEA, CYFR21-1 and NSE in patients with bone metastasis were significantly higher than those in patients without bone metastasis and benign lung diseases. The bone imaging positive group and bone imaging negative group were respectively associated with benign lung disease group The results of CEA, CYFR21-1 and NSE showed significant difference (P <0.01). Conclusion Conventional total body bone imaging is of great significance for clinical judgment, staging and treatment.